🎉 M&A multiples are live!
Check it out!

Gain Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Gain Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Julphar.

Gain Therapeutics Overview

About Gain Therapeutics

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.


Founded

2020

HQ

United States of America
Employees

25

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$42.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Gain Therapeutics Financials

Gain Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Gain Therapeutics achieved revenue of n/a and an EBITDA of -$20.3M.

Gain Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Gain Therapeutics valuation multiples based on analyst estimates

Gain Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.1M n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$22.2M -$20.3M XXX XXX XXX
EBITDA Margin -40177% -Infinity% XXX XXX XXX
Net Profit -$17.6M -$22.3M XXX XXX XXX
Net Margin -31879% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Gain Therapeutics Stock Performance

As of April 15, 2025, Gain Therapeutics's stock price is $2.

Gain Therapeutics has current market cap of $52.0M, and EV of $42.2M.

See Gain Therapeutics trading valuation data

Gain Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$42.2M $52.0M XXX XXX XXX XXX $-0.85

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Gain Therapeutics Valuation Multiples

As of April 15, 2025, Gain Therapeutics has market cap of $52.0M and EV of $42.2M.

Gain Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Gain Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Gain Therapeutics and 10K+ public comps

Gain Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $42.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -2.1x XXX XXX XXX
P/E -2.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -2.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Gain Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Gain Therapeutics Valuation Multiples

Gain Therapeutics's NTM/LTM revenue growth is n/a

Gain Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Gain Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Gain Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Gain Therapeutics and other 10K+ public comps

Gain Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -9% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $0.8M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Gain Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Gain Therapeutics M&A and Investment Activity

Gain Therapeutics acquired  XXX companies to date.

Last acquisition by Gain Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Gain Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Gain Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Gain Therapeutics

When was Gain Therapeutics founded? Gain Therapeutics was founded in 2020.
Where is Gain Therapeutics headquartered? Gain Therapeutics is headquartered in United States of America.
How many employees does Gain Therapeutics have? As of today, Gain Therapeutics has 25 employees.
Who is the CEO of Gain Therapeutics? Gain Therapeutics's CEO is Mr. Gene Mack.
Is Gain Therapeutics publicy listed? Yes, Gain Therapeutics is a public company listed on NAS.
What is the stock symbol of Gain Therapeutics? Gain Therapeutics trades under GANX ticker.
When did Gain Therapeutics go public? Gain Therapeutics went public in 2021.
Who are competitors of Gain Therapeutics? Similar companies to Gain Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Gain Therapeutics? Gain Therapeutics's current market cap is $52.0M
Is Gain Therapeutics profitable? Yes, Gain Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.